Cyanide Toxicity


Practice Essentials

Cyanide toxicity is generally considered to be a rare form of poisoning. However, cyanide exposure occurs relatively frequently in patients with smoke inhalation from residential or industrial fires.[1] In addition, intensive treatment with sodium nitroprusside or long-term consumption of cyanide-containing foods is a possible source of cyanide poisoning.[2, 3] Historically, cyanide has been used as a chemical warfare agent, and it could potentially be an agent for a terrorist attack.[4, 5]

Depending on its form, cyanide may cause toxicity through inhalation, ingestion, dermal absorption, or parenteral administration. Clinical manifestations vary widely, depending on the dose and route of exposure, and may range from minor upper airway irritation to cardiovascular collapse and death within minutes. (See Presentation.) In severe cases, rapid, aggressive therapy consisting of supportive care and antidote administration can be lifesaving. (See Treatment and Medication.)


Cyanide exists in gaseous, liquid, and solid forms. Hydrogen cyanide (HCN, also known as prussic acid) is a volatile liquid that boils at 25.6° C (78.1° F). Potassium and sodium cyanide salts are water soluble, whereas mercury, copper, gold, and silver cyanide salts are poorly water soluble.

In addition, a number of cyanide-containing compounds, known as cyanogens, may release cyanide during metabolism. These include, but are not limited to, cyanogen chloride and cyanogen bromide (gases with potent pulmonary irritant effects), nitriles (R-CN), and the vasodilator nitroprusside sodium, which may produce iatrogenic cyanide poisoning during prolonged or high-dose intravenous (IV) therapy (>10 mcg/kg/min). (See Etiology.)

Industry widely uses nitriles as solvents and in the manufacturing of plastics. Nitriles may release HCN during burning or when metabolized after absorption by the skin or gastrointestinal tract. A number of synthesized and natural compounds produce HCN when burned. These combustion gases likely contribute to the morbidity and mortality from smoke inhalation. Finally, long-term consumption of cyanide-containing foods, such as cassava root or apricot seeds,[3] may lead to cyanide poisoning.

Cyanide as a chemical weapon

HCN (North Atlantic Treaty Organization [NATO] designation AC) is one of two cyanide chemical warfare agents[6, 7, 8] ; the other is cyanogen chloride (NATO designation CK). Cyanide is a rapidly lethal agent when used in enclosed spaces where high concentrations can be achieved easily.[9, 10, 11, 12] In addition, because of the extensive use of cyanide in industry in the United States, this agent presents a credible threat for terrorist use.[7]

Cyanide was first used as a chemical weapon in the form of gaseous HCN in World War I. Starting in 1915, the French military used approximately 4000 tons of cyanide, without notable success. The failure of this measure was probably attributable to the high volatility of cyanide and the inability of the 1- to 2-lb munitions used to deliver the amounts of chemical required for biologic effects.[7, 8]

The introduction of cyanogen chloride by the French in 1916 made available a compound that, being both more toxic and less volatile, was a more effective chemical agent. Other alleged military uses of cyanide include Japanese attacks on China before and during World War II and Iraqi attacks on Kurds in the 1980s.

For related information, see the Disaster Preparedness and Aftermath Resource Center.[13, 14]


Cyanide exposure most often occurs via inhalation or ingestion, but liquid cyanide can be absorbed through the skin or eyes. Once absorbed, cyanide enters the blood stream and is distributed rapidly to all organs and tissues in the body.[15]

Inside cells, cyanide attaches itself to ubiquitous metalloenzymes, rendering them inactive. Its principal toxicity results from inactivation of cytochrome oxidase (at cytochrome a3), thus uncoupling mitochondrial oxidative phosphorylation and inhibiting cellular respiration, even in the presence of adequate oxygen stores. Cellular metabolism shifts from aerobic to anaerobic, with the consequent production of lactic acid. Consequently, the tissues with the highest oxygen requirements (brain and heart) are the most profoundly affected by acute cyanide poisoning.

The LCt50 (the concentration-time product capable of killing 50% of the exposed group) for hydrogen cyanide is 2500-5000 mg/min/m3. Vapor exposures in high concentrations (at or above the LCt50) typically can cause death in 6-8 minutes.[4] The lethal oral doses of HCN and cyanide salts are estimated to be 50 mg and 100-200 mg, respectively. For skin exposures, the LD50 (the dose capable of killing 50% of the exposed group) is estimated to be 100 mg/kg.

Cyanogen chloride is used in mining and metalworking, and thus may be involved in an industrial accident. By nature of its chlorine moiety, cyanogen chloride causes irritation of the eyes and respiratory tract and potential delayed pulmonary toxicity similar to chlorine or phosgene gases. In high concentrations (eg, in enclosed spaces), this agent is rapidly acting and lethal, causing death within 6-8 minutes if inhaled at doses at or above its LCt50 of 11,000 mg/min/m3.

Defective cyanide metabolism due to rhodanese deficiency may explain development of Leber optic atrophy, leading to subacute blindness. Cyanide also may cause some of the adverse effects associated with chronic smoking, such as tobacco amblyopia.


Smoke inhalation, suicidal ingestion, and industrial exposures are the most frequent sources of cyanide poisoning. Treatment with sodium nitroprusside or long-term consumption of cyanide-containing foods is a possible source. Historically, cyanide has been used as a chemical warfare agent, and it could potentially be an agent for a terrorist attack.[4, 5]

Smoke inhalation

Smoke inhalation during house or industrial fires is the major source of cyanide poisoning in the United States. Individuals with smoke inhalation from enclosed space fires who have soot in the mouth or nose, altered mental status, or hypotension may have significant cyanide poisoning (blood cyanide concentrations >40 mmol/L or approximately 1 mg/L).

Many compounds containing nitrogen and carbon may produce hydrogen cyanide (HCN) gas when burned. Some natural compounds (eg, wool, silk) produce HCN as a combustion product.[6, 16] Household plastics (eg, melamine in dishware, acrylonitrile in plastic cups), polyurethane foam in furniture cushions, and many other synthetic compounds may produce lethal concentrations of cyanide when burned under appropriate conditions of oxygen concentration and temperature.

Intentional poisoning

Cyanide ingestion is an uncommon, but effective, means of suicide.[17] These cases typically involve health-care and laboratory workers who have access to the cyanide salts found in hospital and research laboratories.

Industrial exposure

Countless industrial sources of cyanides exist. Cyanides are used particularly in the metal trades, mining, jewelry manufacturing, dyeing, photography, and agriculture. Specific industrial processes involving cyanide include metal cleaning, reclaiming, or hardening; fumigation; electroplating; and photo processing.[5] In addition, industry uses cyanides in the manufacture of plastics, as reactive intermediates in chemical synthesis, and as solvents (in the form of nitriles).

Exposure to salts and cyanogens occasionally causes poisonings; however, a significant risk for multiple casualties occurs when these products come into contact with mineral acids because HCN gas is produced. A mass casualty incident may develop in an industrial accident in which cyanogen chloride comes in contact with water (eg, during fire-fighting). Containers of cyanogen chloride may rupture or explode if exposed to high heat or following prolonged storage.

Iatrogenic exposure

The vasodilator nitroprusside sodium, when used in high doses or over a period of days, can produce toxic blood concentrations of cyanide. Patients with low thiosulfate reserves (eg, malnourished, postoperative) are at increased risk for developing symptoms, even with therapeutic dosing. Resultant confusion and combativeness initially may be mistaken as intensive care unit (ICU) syndrome (ie, sundowning). Problems may be avoided by coadministration of hydroxocobalamin or sodium thiosulfate.

Ingestion of cyanide-containing supplements or plants

Ingestion of cyanide-containing supplements is rare. Amygdalin (synthetic laetrile, also marketed as vitamin B-17), which contains cyanide, was postulated to have anticancer properties due to the action of cyanide on cancer cells. However, laetrile showed no anticancer activity in human clinical trials in the 1980s and is not available in the United States,[18] although it can be purchased on the Internet.[19]

Amygdalin can be found in the pits of many fruits, such as apricots and papayas; in raw nuts; and in plants such as lima beans, clover, and sorghum. Amygdalin can be hydrolyzed to hydrogen cyanide, and ingestion of large quantities of such foods may result in toxicity.[5]


United States statistics

Cyanide may be a major contributor to the morbidity and mortality observed in the approximately 5000-10,000 deaths from smoke inhalation occurring each year in the United States. Suicidal exposures are rarely reported to poison centers: intentional exposures accounted for 19 of the 187 cyanide poisoning cases reported to the American Association of Poison Control Centers in 2014.[20] However, a rapidly fatal suicide from cyanide salts in an adult patient might easily be mistaken for sudden death from myocardial infarction, pulmonary embolus, or ventricular dysrhythmia.

Suicide by cyanide poisoning occurs predominantly in males, as does industrial exposure. Leber optic atrophy has shown a very strong male predominance in European studies.

Deliberate ingestion of cyanide occurs mostly in adults. Smoke inhalation and chronic cyanide poisoning affect all ages.


The prognosis in cyanide toxicity is good for patients who have only minor symptoms that do not necessitate the administration of antidotes. The prognosis is reasonably good for patients with moderate symptoms if rapid supportive intervention and effective antidotal therapy are provided. Suicidal poisonings tend to have severe outcomes because large doses are often involved.

The prognosis in patients with cyanogen poisoning is better in those with low-level exposures with minor symptoms that resolve after they are removed from exposure. The prognosis is fair for patients with seizures or recent-onset apnea if antidotes can be administered rapidly. The prognosis is generally poor in patients who suffer cardiac arrest secondary to cyanide toxicity, even if antidotes are administered promptly.


According to the American Association of Poison Control Centers Toxic Exposure Surveillance System, 7 of the 202 cyanide exposure cases in 2012 were fatal.[20] Cyanide induces fatality in seconds to minutes following inhalation or intravenous injection, in minutes following ingestion of soluble salts, or minutes (hydrogen cyanide) to several hours (cyanogens) after skin absorption.

Individuals who survive cyanide poisoning are at risk for central nervous system dysfunction, such as anoxic encephalopathy. Acute and delayed neurologic manifestations (Parkinson-like syndrome, other movement disorders, neuropsychiatric sequelae) have been reported.

Patient Education

Educate patients using cyanide in their jobs about safe work practices, including the use of personal protective equipment. Certain cyanide compounds are well absorbed dermally; thus, gloves and other forms of skin protection should be worn. Moreover, cyanide compounds should be scrupulously isolated from exposure to acids.

Educate patients with cancer or human immunodeficiency virus (HIV) who might purchase anticancer supplements over the Internet about the possible risks from such medicines. Encourage them to discuss supplement use with their oncologist.

Patients who have been exposed to cyanide should be educated about potential neurologic sequelae and the importance of follow-up evaluation. Patients treated with hydroxocobalamin who develop skin erythema should be cautioned to avoid exposure to sunlight while the discoloration persists, due to possible photosensitivity. These patients may also develop red discoloration of their urine as an expected side effect that resolves without treatment.

For patient education information, see Personal Protective Equipment , theFirst Aid and Emergency Center and the Lung Disease and Respiratory Health Center, as well as Cyanide Poisoning and Smoke Inhalation.


Key historical features for suspected hydrogen cyanide (HCN) casualties include the following[5, 4] :

The delay between exposure and the onset of symptoms depends on the type of cyanide involved, the route of entry, and the dose. Rapidity of symptom onset, depending on the type of cyanide exposure, occurs in the following order (most rapid to least rapid): gas, soluble salt, insoluble salt, and cyanogens.

A history of recent depression in the patient with sudden collapse or altered mental status, metabolic acidosis, and tachyphylaxis in an intensive care unit patient who is receiving nitroprusside should evoke suspicion of the diagnosis.

Symptoms may include the following:

Symptoms after exposure to high vapor concentrations may include the following:

Symptoms after exposure to lower vapor concentrations or after ingestion or liquid exposure may include the following:

Patients exposed to cyanogen chloride experience severe eye and mucous membrane irritation.[21] Low-dose exposure results in rhinorrhea, bronchorrhea, and lacrimation. Inhalational exposure results in dyspnea, cough, and chest discomfort. Onset of symptoms after exposure to nitriles (acetonitrile and/or propionitrile) may be significantly delayed.

Physical Examination

Physical findings of cyanide exposure are generally nonspecific, yet the onset of illness may be dramatic. Findings can include the following:

Neurologic symptoms may include the following:

Classically, the skin of a cyanide-poisoned patient is described as cherry red in color due to elevated venous oxygen content resulting from failure of tissues to extract oxygen. In addition, arterialization of the venous blood may also be noted during phlebotomy or examination of the retinal veins. Alternatively, patients may be cyanotic after prolonged respiratory failure and shock. Despite its name, cyanosis is not a prominent finding of cyanide poisoning. Finally, many patients with cyanide poisoning have normal-appearing skin.

Approach Considerations

The workup in patients with cyanide exposure may include the studies discussed below.

Arterial and venous blood gases

Cyanide toxicity is characterized by a normal arterial oxygen tension and an abnormally high venous oxygen tension, resulting in a decreased arteriovenous oxygen difference (< 10%). A high-anion-gap metabolic acidosis is a hallmark of significant cyanide toxicity.[9, 22] Apnea may result in combined metabolic and respiratory acidosis.

Blood lactate level

Elevation in the blood lactate level is a sensitive marker for cyanide toxicity. A plasma lactate concentration of greater than 10 mmol/L in smoke inhalation or greater than 6 mmol/L after reported or strongly suspected pure cyanide poisoning suggests significant cyanide exposure.[23]

Red blood cell or plasma cyanide concentration

Cyanide blood concentrations are not generally available in time to aid in the treatment of acute poisoning, but may provide subsequent confirmation. In cyanogen exposures, these tests provide documentation for therapeutic use, which may last several days.

The preferred test is a red blood cell cyanide concentration. With this method, mild toxicity is observed at concentrations of 0.5-1.0 μg/mL. Concentrations of 2.5 μg/mL and higher are associated with coma, seizures, and death. Blood cyanide concentrations may artificially increase after sodium nitrite (antidote) administration, because of in vitro release of cyanide from cyanomethemoglobin during the analytical procedure by strong acid used in analysis.

Carboxyhemoglobin level or blood carbon monoxide concentration

Carboxyhemoglobin (HbCO) level (by co-oximetry) or blood carbon monoxide concentration (by infrared spectroscopy) may be obtained in patients with smoke inhalation to rule out concurrent exposure. HbCO measurements may be artificially elevated in blood samples drawn after hydroxocobalamin administration.[24]

Methemoglobin level

A methemoglobin level is especially important in cyanotic patients. The presence of methemoglobin suggests that little or no free cyanide is available for binding, because methemoglobin vigorously binds cyanide to form cyanomethemoglobin (which is not measured as methemoglobin).

Methemoglobin concentrations provide a guide for continued therapy after the use of methemoglobin-inducing antidotes, such as sodium nitrite. Elevated levels of methemoglobin (>10%) indicate that further nitrite therapy is not indicated and, in fact, may be dangerous.

Electrocardiogram (ECG)

On ECG, nonspecific findings predominate. Abnormalities may include the following[25] :

In some cases, shortening of the ST segment with eventual fusion of the T wave into the QRS complex has been observed.


No imaging studies are indicated acutely for cyanide exposure, but magnetic resonance imaging (MRI) may be useful during the evaluation of postexposure neurologic sequelae.

Fluorescein staining and slit-lamp examination of the eyes may be necessary following decontamination to assess corneal integrity.

Approach Considerations

Administer a cyanide antidote if the diagnosis of cyanide toxicity is strongly suspected, without waiting for laboratory confirmation. Available antidotes are hydroxocobalamin (Cyanokit) and sodium thiosulfate and sodium nitrite (Nithiodote). Both are given intravenously.

Patients who present with more than minimal symptoms that resolve without treatment should be admitted for observation and supportive care. In patients with acute poisoning from hydrogen cyanide (HCN) gas or soluble salts, the principal acute care concerns are hemodynamic instability and cerebral edema. The continuous cardiac monitoring, respiratory and cardiovascular support, and frequent neurologic evaluation these patients require is generally best provided in an intensive care unit.

Conversely, acute poisoning from cyanogens (nitriles) or poorly soluble salts may not manifest or become life-threatening for several hours after exposure. These patients require a 24-hour observation period.[26, 27]

Oxygenation should be optimized and continuous cardiac monitoring provided. Depending on the severity of symptoms, endotracheal intubation may be necessary to optimize oxygen delivery and protect the airway. Serum lactate concentrations, chemistries, and arterial or venous blood gases should be monitored.

Patients should be reevaluated 7-10 days after discharge from the hospital.[28] Delayed onset of Parkinson-like syndrome or neuropsychiatric sequelae may be noted on followup.

Special concerns in pregnancy

Fetal demise is possible in cyanide poisoning. Aggressive support and antidotal treatment of the mother is paramount. An obstetric evaluation following stabilization of the mother is essential. Therapeutic abortion may be indicated in the presence of fetal demise.

Prehospital Care

Use of personal protective equipment is essential at many cyanide exposure scenes. Respiratory protection against hydrogen cyanide gas may be needed at fires and industrial accidents. Certain cyanide compounds can be absorbed dermally; emergency services personnel should wear gloves and other forms of skin protection.

Appropriate prehospital measures may include the following[7, 8] :

Aggressive airway management with delivery of 100% oxygen can be lifesaving. (Although theoretically useless, supportive care with administration of oxygen alone has proven effective in a number of poisonings.) It can also treat concomitant carbon monoxide exposure, pending measurement of blood levels.

Administer cyanide antidotes as soon as possible.[29, 26, 27] While not carried by all emergency medical technicians, some first responders do have protocols to administer hydroxocobalamin in the field. As a temporizing measure, amyl nitrite ampules can be crushed and their contents poured onto a gauze pad and placed in front of the patient's mouth, if the patient is breathing spontaneously, or ventilated into an apneic patient using a bag-valve-mask.

Emergency Department Care

Initial emergency department care for patients with cyanide exposure is identical to that provided in the prehospital phase. Provide supportive care, including the following:

Decontaminate the patient with removal of clothing/skin flushing and/or activated charcoal (1g/kg), as appropriate. Activated charcoal should be given after oral exposure in alert patients who are able to protect the airway or after endotracheal intubation in unconscious patients. In recent ingestions, activated charcoal may be preceded by gastric lavage. The gastric aspirate may cause secondary contamination and should be viewed as hazardous.

Administer hydroxocobalamin or sodium thiosulfate and sodium nitrite if the diagnosis is strongly suspected. Do not wait for laboratory confirmation.

Cyanide Antidotes

Antidotes to cyanide include hydroxocobalamin and sodium nitrite and sodium thiosulfate. Sodium thiosulfate may be given in combination with sodium nitrite or hydroxocobalamin, or may be given alone. These agents are administered intravenously.


Hydroxocobalamin, which is considered the drug of choice in continental Europe and Australia, is approved by the US Food and Drug Administration (FDA) for treating known or suspected cyanide poisoning.[30, 31] Coadministration of sodium thiosulfate (through a separate line or sequentially) has been suggested to have a synergistic effect on detoxification.

Hydroxocobalamin combines with cyanide to form cyanocobalamin (vitamin B-12), which is renally cleared.[32] Alternatively, cyanocobalamin may dissociate from cyanide at a slow enough rate to allow for cyanide detoxification by the mitochondrial enzyme rhodanese.

A review by Hall et al notes that hydroxocobalamin has not been associated with clinically significant toxicity in antidotal doses compared with other cyanide antidotes. Hydroxocobalamin has a rapid onset of action, neutralizes cyanide without interfering with cellular oxygen use, is conducive to prehospital use due to its tolerability and safety profiles, and is safe for use in patients with smoke inhalation.[33]

Adverse effects of hydroxocobalamin administration include transient hypertension (a benefit in hypotensive patients), reddish brown skin, mucous membrane and urine discoloration, and rare anaphylaxis and anaphylactoid reactions. Because of its bright red color, it also interferes with co-oximetry (about a 5% increase in carboxyhemoglobin levels) and blood chemistry testing (bilirubin, creatinine kinase and possibly liver enzymes, creatinine, phosphorus, glucose, magnesium, and iron levels).[34] It can also interfere with hemodialysis.[35]

Certain medications should not be administered simultaneously or through the same line as hydroxocobalamin. These include diazepam, dopamine, dobutamine, and sodium thiosulfate.

Sodium nitrite and sodium thiosulfate

Sodium nitrite and sodium thiosulfate are often used in combination and are currently considered second-line therapy after hydroxocobalamin. Sodium nitrite is rapidly effective but can cause life-threatening toxicity, whereas sodium thiosulfate has a somewhat delayed effect but is far safer.

Sodium nitrite induces methemoglobin in red blood cells, which combines with cyanide, thus releasing cytochrome oxidase enzyme. Sodium thiosulfate donates a sulfur atom necessary for the transformation of cyanide to thiocyanate by rhodanese, thus increasing the activity of the endogenous detoxification system. The thiocyanate is then renally excreted.

Sodium nitrite should not be used in patients with smoke inhalation unless their carboxyhemoglobin concentration is very low (< 10%). The induction of methemoglobinemia by sodium nitrite compounds the effect of any existing carboxyhemoglobinemia, significantly reduces the oxygen-carrying capacity of blood. In addition, vasodilation from sodium nitrite may result in significant hypotension and cardiovascular collapse.[29]

Appropriate dosing of sodium nitrite has not been established in children. Consequently, these patients are at increased risk for excessive methemoglobinemia, hypotension, or both.

Inpatient Care

Optimize oxygenation. Monitor disease resolution by clinical criteria, serial plasma lactate concentrations, and arterial and venous blood gases. Perform serial electrocardiograms (ECGs) for patients with cardiac dysrhythmias or complaints of chest pain. Monitor for delayed onset of pulmonary edema in those presenting with evidence of respiratory irritation. Discharge the patient when neurologic status and cardiovascular status have normalized and acidosis and other metabolic abnormalities have resolved.


Avoid transfer of patients with acute cyanide toxicity. However, transfer the patient if antidotes and intensive care are unavailable and if rapid, appropriate medical transport can be assured. Ideally, transfer patients to a regional toxicology treatment center.

Provide medical stabilization (eg, airway, hemodynamic parameters) before transfer. Transfer with an advanced cardiac life support (ACLS) level of service under continuous cardiac monitoring with supplemental oxygen and intravenous access.

Deterrence and Prevention

Smoke alarms significantly reduce the incidence of serious smoke inhalation injury. Workplaces using cyanides should have engineering controls in place to avoid inadvertent exposures. Workers should be provided with personal protective equipment and training; they should be instructed to avoid contact between cyanide salts and mineral acids or other compounds with low pH.

Patients receiving sodium nitroprusside at high doses or for more than 5 days should have monitoring of blood cyanide or thiocyanate concentrations. Alternatively, these patients can be treated prophylactically with sodium thiosulfate or hydroxocobalamin to reduce the risk of iatrogenic cyanide poisoning.


Consultation with a medical toxicologist or a poison control center is recommended. They should be contacted immediately upon consideration of cyanide as a diagnosis, given the critical nature of these cases.[7] They can provide recommendations regarding the most effective available antidotal therapy, as well as insight into potential sources of poisoning (eg, industrial) that may place others at risk. Online resources may also be consulted (see the chart below).

Chemical terrorism agents and syndromes: signs and symptoms (PDF) (Copyright University of North Carolina at Chapel Hill)

Consult with law enforcement authorities and the Federal Bureau of Investigation (FBI) in any suspected terrorist incident.

Medication Summary

Oxygen is the initial agent used in suspected or confirmed cyanide poisoning. Sodium bicarbonate is used in patients with severe poisoning that has produced marked lactic acidosis. Epinephrine is used to support cerebral and coronary perfusion in low-flow states.

Antidotal therapy is indicated for any patient in whom the diagnosis of cyanide toxicity is considered on clinical grounds, even before laboratory confirmation. Activated charcoal can be used in patients presenting after ingestion of cyanide salts or organic cyanides.

Anticonvulsants are used as indicated. Lorazepam is the drug of choice; midazolam and phenobarbital are second-line agents.

Cyanide antidotes are the key medications for hydrogen cyanide (HCN) poisoning. Hydroxocobalamin (HCO, vitamin B-12) is the first-line therapy for cyanide toxicity. It functions by binding cyanide to its cobalt ion to form cyanocobalamin, which is essentially nontoxic and is cleared renally.[36, 33] HCO can be combined with sodium thiosulfate for accelerated detoxification. Amyl nitrite is an alternative temporizing therapy; it may be useful in the absence of intravenous (IV) access (eg, in industrial settings).

Sodium thiosulfate enhances the conversion of cyanide to thiocyanate , which is renally excreted. Thiosulfate has a somewhat delayed effect and thus is typically used with sodium nitrite for faster antidote action. Sodium nitrite must be used with caution because it may result in significant hypotension and cardiovascular collapse, in addition to generating dangerous levels of methemoglobin. However, in cases of smoke inhalation in which cyanide toxicity is suspected, administration of sodium thiosulfate is safe.

Hydroxocobalamin (Cyanokit)

Clinical Context:  Hydroxocobalamin contains cobalt ion, which is able to bind to cyanide with greater affinity than cytochrome oxidase to form nontoxic cyanocobalamin (vitamin B-12), which is excreted in urine. Hydroxocobalamin has few adverse effects and is tolerated by critically ill patients. It is well tolerated by patients with concomitant carbon monoxide poisoning, because unlike sodium nitrite it has no effect on the oxygen-carrying capacity of hemoglobin.

Hydroxocobalamin may be used in combination with sodium thiosulfate for treatment of acute cyanide toxicity. Low-dose hydroxocobalamin in combination with sodium thiosulfate has been used successfully to prevent cyanide toxicity in patients receiving prolonged sodium nitroprusside infusions.

The disadvantages of hydroxocobalamin are that a large dose is required for antidotal efficacy and that it is available in the United States only in very dilute solutions. It can cause transient hypertension, allergic reactions (rarely including anaphylaxis and angioedema), and a reddish discoloration of body fluids and urine.

Sodium thiosulfate & sodium nitrite (Nithiodote)

Clinical Context:  Sodium nitrite induces methemoglobin formation and vasodilation. Sodium thiosulfate has a slower mechanism of action. It donates sulfur, which is used as a substrate by rhodanese and other sulfur transferases for detoxification of cyanide to thiocyanate. In patients with concomitant carbon monoxide poisoning, for whom sodium nitrite is contraindicated, sodium thiosulfate can be used alone; sodium thiosulfate can also be administered with hydroxocobalamin in severe cases.

The recommended dose assumes a patient hemoglobin level of 12 mg/dL; dosage adjustment may be necessary in patients with anemia. Half the original dose may be repeated in 1 hour if the patient continues to exhibit signs of cyanide toxicity.

Amyl nitrite

Clinical Context:  The nitrite ions in amyl nitrite react with hemoglobin to form methemoglobin, which unites with cyanide to form cyanomethemoglobin. Amyl nitrite rushed and contents poured onto a gauze and placed in front of patient's mouth pearls can be crushed and inhaled by a spontaneously breathing patient or ventilated into an apneic patient using a bag-valve-mask device; this is a temporizing measure until IV access can be established.

The effect of an ampule lasts approximately 3 minutes; separate administration by at least 30 seconds to allow patient to oxygenate. Due to the volatile nature of this compound, rescuers should ensure that they themselves have an adequate fresh air supply and can maintain a sufficient distance from the amyl nitrite source.

Activated charcoal (Actidose-Aqua, EZ-Char, Kerr Insta-Char)

Clinical Context:  Activated charcoal binds cyanide poorly; 1 g of charcoal adsorbs only 35 mg of cyanide. Nonetheless, a 1-g/kg dose of charcoal could potentially bind a lethal dose of cyanide and has a low risk profile. Consequently, charcoal should be administered as soon as possible following oral ingestion of cyanide salts or organic cyanides.

Sodium bicarbonate (Neut)

Clinical Context:  Sodium bicarbonate may be required in large doses for alkalization.

Class Summary

Cyanide is a cellular toxin that binds to cytochrome oxidase, inhibiting cellular respiration. Antidotes either directly counteract cyanide's toxicity on the electron transport chain or help the body eliminate the cyanide molecule. Administration of antidotes is critical for life-threatening intoxication.

Gastrointestinal (GI) decontamination with oral activated charcoal is selectively used in the emergency treatment of poisoning caused by some drugs and chemicals. The network of pores present in activated charcoal adsorbs 100-1000 mg of drug per gram of charcoal. Consider decontamination with activated charcoal in any patient who presents within 4 hours after the ingestion.

Alkalinizing agents are used in severe poisoning, which causes marked lactic acidosis.

Lorazepam (Ativan)

Clinical Context:  Lorazepam is the drug of choice for cyanide-induced seizures. It is a sedative hypnotic with a rapid onset of effect and a relatively long half-life. By increasing the action of GABA, a major inhibitory neurotransmitter in the brain, lorazepam may depress all levels of the central nervous system, including the limbic and reticular formation.

Pentobarbital (Nembutal)

Clinical Context:  Pentobarbital is a short-acting barbiturate that interferes with transmission of impulses from the thalamus to the cortex. It has sedative, hypnotic, and anticonvulsant properties. It is a second-line drug for treatment of drug-induced seizures.

Class Summary

Cyanide inhibits brain glutamate decarboxylase, which causes a decrease in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and contributes to convulsions. Therefore, anticonvulsant drugs such as benzodiazepines or barbiturates, which act at the GABA receptor complex, can help control seizures.

Epinephrine (EpiPen, EpiPen Jr, Adrenaclick, Auvi-Q, Adrenalin)

Clinical Context:  Epinephrine is the drug of choice for treating anaphylactoid reactions. It has alpha-agonist effects that include increased peripheral vascular resistance, reversed peripheral vasodilatation, systemic hypotension, and vascular permeability. Its beta-agonist effects include bronchodilatation, chronotropic cardiac activity, and positive inotropic effects.

Class Summary

These agents augment coronary and cerebral blood flow during the low-flow states associated with cyanide poisoning.

What is cyanide toxicity?How is cyanide used as a chemical weapon?What is the pathophysiology of cyanide toxicity?What is the pathophysiology of cyanide chloride toxicity?What are the most common etiologies of cyanide toxicity?What is the role of smoke inhalation in the etiology of cyanide toxicity?Which individuals are most likely to ingest cyanide as a means of suicide?What is the role of industrial exposure in the etiology of cyanide toxicity?What is the role of iatrogenic exposure in the etiology of cyanide toxicity?Which foods and supplements may cause cyanide toxicity?What is the incidence of cyanide toxicity in the US?What is the prognosis of cyanide toxicity?What is the mortality rate of cyanide toxicity?What information about cyanide toxicity should patients be given?Which history is characteristic of cyanide toxicity?Which factors affect the onset of symptoms of cyanide toxicity?What are the symptoms of cyanide toxicity?What are the symptoms of cyanide toxicity after exposure to high vapor concentrations?What are the symptoms of cyanide toxicity after exposure to lower vapor concentrations or after ingestion or liquid exposure?What the symptoms of cyanide toxicity from cyanogen chloride exposure?Which physical findings are characteristic of cyanide toxicity?What are the neurologic symptoms of cyanide toxicity?Which dermatologic findings are characteristic of cyanide toxicity?What is the significance of the presence of lactic acidosis in the diagnosis of cyanide toxicity?Which conditions should be included in the differential diagnoses of cyanide toxicity?Which agents have similar toxicity presentations to cyanide poisoning?What are the differential diagnoses for Cyanide Toxicity?What is included in the evaluation of cyanide toxicity?What is the role of arterial and venous blood gases in the diagnosis of cyanide toxicity?What is the role of blood lactate levels in the diagnosis of cyanide toxicity?How are red blood cell cyanide concentrations assessed in the diagnosis of cyanide toxicity?What is the role of carboxyhemoglobin levels or blood carbon monoxide concentrations in the diagnosis of cyanide toxicity?What is the role of methemoglobin levels in the diagnosis of cyanide toxicity?What is the role of electrocardiogram (ECG) in the diagnosis of cyanide toxicity?What is the role of imaging studies in the diagnosis of cyanide toxicity?When are fluorescein staining and slit-lamp exam indicated in the diagnosis of cyanide toxicity?What is the initial treatment for cyanide toxicity?What are special concerns for pregnant patients with cyanide toxicity?When is personal protective equipment indicated in the management of cyanide toxicity?What is included in prehospital care for cyanide toxicity?What is included in emergency department care (ED) care for cyanide toxicity?What are antidotes for cyanide toxicity?How effective is hydroxocobalamin in treating cyanide toxicity?How effective are sodium nitrite and sodium thiosulfate in treating cyanide toxicity?What is included in inpatient care for patients affected by cyanide toxicity?When is transfer indicated for management of cyanide toxicity?How is cyanide toxicity prevented?Which specialist consultations are helpful in the management of cyanide toxicity?Which medications are used in the treatment of cyanide toxicity?Which medications in the drug class Alpha/Beta Adrenergic Agonists are used in the treatment of Cyanide Toxicity?Which medications in the drug class Anticonvulsants, Other are used in the treatment of Cyanide Toxicity?Which medications in the drug class Antidotes are used in the treatment of Cyanide Toxicity?


Inna Leybell, MD, Clinical Assistant Professor, Department of Emergency Medicine, NYU Langone Medical Center

Disclosure: Nothing to disclose.


Carlos J Roldan, MD, FAAEM, FACEP, Professor of Emergency Medicine, Department of Emergency Medicine, McGovern Medical School, University of Texas Health Science Center at Houston; Assistant Professor of Pain Medicine, Department of Pain Medicine, MD Anderson Cancer Center

Disclosure: Nothing to disclose.

Colleen M Rivers, MD, Senior Fellow in Medical Toxicology, New York City Poison Control Center, Bellevue Hospital Center

Disclosure: Nothing to disclose.

Stephen W Borron, MD, MS, FAAEM, FACEP, FAACT, FACMT, Professor of Emergency Medicine and Medical Toxicology, Division of Medical Toxicology, Department of Emergency Medicine, Paul L Foster School of Medicine, Texas Tech University Health Sciences Center; Associate Medical Director, West Texas Regional Poison Center

Disclosure: Received consulting fee from Meridian Pharmaceuticals for consulting.

Chief Editor

Michael A Miller, MD, Clinical Professor of Emergency Medicine, Medical Toxicologist, Department of Emergency Medicine, Texas A&M Health Sciences Center; CHRISTUS Spohn Emergency Medicine Residency Program

Disclosure: Nothing to disclose.


Frederic J Baud, MD Director, Professor, Toxicological and Medical Intensive Care Unit, Hôpital Lariboisiere of Paris, France

Disclosure: Nothing to disclose.

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Robert S Hoffman, MD, FAACT, FACMT Associate Professor, Departments of Emergency Medicine and Medicine, Clinical Pharmacology, New York University School of Medicine, Consulting Staff, Department of Emergency Services, Bellevue and New York University Hospital

Robert S Hoffman, MD, FAACT, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, American College of Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

David C Lee, MD Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School

David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Jorge A Martinez, MD, JD Clinical Professor, Department of Internal Medicine, Louisiana State University School of Medicine in New Orleans; Clinical Instructor, Department of Surgery, Tulane School of Medicine

Jorge A Martinez, MD, JD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Cardiology, American College of Emergency Physicians, American College of Physicians, and Louisiana State Medical Society

Disclosure: Nothing to disclose.

Heather Murphy-Lavoie, MD, FAAEM Assistant Professor, Assistant Residency Director, Emergency Medicine Residency, Associate Program Director, Hyperbaric Medicine Fellowship, Section of Emergency Medicine and Hyperbaric Medicine, Louisiana State University School of Medicine in New Orleans; Clinical Instructor, Department of Surgery, Tulane University School of Medicine

Heather Murphy-Lavoie, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Society for Academic Emergency Medicine, and Undersea and Hyperbaric Medical Society

Disclosure: Nothing to disclose.

Lewis S Nelson, MD, FACEP, FAACT, FACMT Professor, Department of Emergency Medicine, New York University School of Medicine; Attending Physician, Department of Emergency Medicine, Bellevue Hospital Center, New York University Medical Center

Lewis S Nelson, MD, FACEP, FAACT, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Andre Pennardt, MD, FACEP, FAAEM, FAWM Clinical Associate Professor of Emergency Medicine, Georgia Health Sciences University; Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Department of Emergency Medicine, Eisenhower Army Medical Center

Andre Pennardt, MD, FACEP, FAAEM, FAWM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Association of Military Surgeons of the US, International Society for Mountain Medicine, National Association of EMS Physicians, Special Operations Medical Association, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Erik D Schraga, MD Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Suzanne White, MD Medical Director, Regional Poison Control Center at Children's Hospital, Program Director of Medical Toxicology, Associate Professor, Departments of Emergency Medicine and Pediatrics, Wayne State University School of Medicine

Suzanne White, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Clinical Toxicology, American College of Epidemiology, American College of Medical Toxicology, American Medical Association, and Michigan State Medical Society

Disclosure: Nothing to disclose.


  1. Holstege CP, Kirk MA. Cyanide and Hydrogen Sulfide. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, eds. Goldfrank's Toxicologic Emergencies. 10th ed. New York, NY: McGraw-Hill Education; 2015. Chapter 126.
  2. Abraham K, Buhrke T, Lampen A. Bioavailability of cyanide after consumption of a single meal of foods containing high levels of cyanogenic glycosides: a crossover study in humans. Arch Toxicol. 2016 Mar. 90 (3):559-74. [View Abstract]
  3. Akyildiz BN, Kurtoglu S, Kondolot M, Tunc A. Cyanide poisoning caused by ingestion of apricot seeds. Ann Trop Paediatr. 2010. 30(1):39-43. [View Abstract]
  4. Armstrong J. Chemical warfare. RN. 2002 Apr. 65(4):32-9; quiz 40. [View Abstract]
  5. Brennan RJ, Waeckerle JF, Sharp TW, Lillibridge SR. Chemical warfare agents: emergency medical and emergency public health issues. Ann Emerg Med. 1999 Aug. 34(2):191-204. [View Abstract]
  6. Baud FJ. Cyanide: critical issues in diagnosis and treatment. Hum Exp Toxicol. 2007 Mar. 26(3):191-201. [View Abstract]
  7. Greenfield RA, Brown BR, Hutchins JB, Iandolo JJ, Jackson R, Slater LN, et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci. 2002 Jun. 323(6):326-40. [View Abstract]
  8. Rosenbloom M, Leikin JB, Vogel SN, Chaudry ZA. Biological and chemical agents: a brief synopsis. Am J Ther. 2002 Jan-Feb. 9(1):5-14. [View Abstract]
  9. Baskin SI, Brewer TG. Cyanide poisoning. Cyanide poisoning. Medical Aspects of Chemical and Biological Warfare. 1997. 271-286.
  10. Morocco AP. Cyanides. Crit Care Clin. 2005 Oct. 21(4):691-705, vi. [View Abstract]
  11. Sidell FR, Patrick WC, Dashiell TR. Cyanide. Jane's Chem-Bio Handbook. 1998. 79-88.
  12. USACHPPM. Cyanide. USACHPPM Tech Guide 244: The Medical NBC Battlebook. 1999. V: 36-37.
  13. Burda AM, Sigg T. Pharmacy preparedness for incidents involving weapons of mass destruction. Am J Health Syst Pharm. 2001 Dec 1. 58(23):2274-84. [View Abstract]
  14. Lynch EL, Thomas TL. Pediatric considerations in chemical exposures: are we prepared?. Pediatr Emerg Care. 2004 Mar. 20(3):198-208. [View Abstract]
  15. Zheng A, Dzombak DA, Luthy RG. Formation of free cyanide and cyanogen chloride from chloramination of publicly owned treatment works secondary effluent: laboratory study with model compounds. Water Environ Res. 2004 Mar-Apr. 76(2):113-20. [View Abstract]
  16. Schnepp R. Cyanide: sources, perceptions, and risks. J Emerg Nurs. 2006 Aug. 32(4 Suppl):S3-7. [View Abstract]
  17. Musshoff F, Schmidt P, Daldrup T, Madea B. Cyanide fatalities: case studies of four suicides and one homicide. Am J Forensic Med Pathol. 2002 Dec. 23(4):315-20. [View Abstract]
  18. National Cancer Institute. Cancer topics: Laetrile/Amygdalin. 11/21/2005.
  19. Dang T, Nguyen C, Tran PN. Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion. Case Rep Emerg Med. 2017. 2017:4289527. [View Abstract]
  20. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila). 2015 Dec. 53 (10):962-1147. [View Abstract]
  21. Department of the Army. Blood agents (Cyanogens). Field Manual 8-285: Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. 1995. VI: 1-2.
  22. Baud FJ, Borron SW, Mégarbane B, Trout H, Lapostolle F, Vicaut E, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med. 2002 Sep. 30(9):2044-50. [View Abstract]
  23. Baud FJ, Barriot P, Toffis V, Riou B, Vicaut E, Lecarpentier Y, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med. 1991 Dec 19. 325(25):1761-6. [View Abstract]
  24. Lee J, Mukai D, Kreuter K, et al. Potential interference by hydroxocobalamin on co-oximetry hemoglobin measurements during cyanide and smoke inhalation treatments. Ann Emerg Med. 2007. 49(6):802-805. [View Abstract]
  25. Fortin JL, Desmettre T, Manzon C, Judic-Peureux V, Peugeot-Mortier C, Giocanti JP, et al. Cyanide poisoning and cardiac disorders: 161 cases. J Emerg Med. 2010 May. 38(4):467-76. [View Abstract]
  26. USAMRICD. Cyanide. Field Management of Chemical Casualties Handbook. 1996. 37-40.
  27. USAMRICD. Cyanide. Medical Management of Chemical Casualties Handbook. 1999. 38-58.
  28. Martin CO, Adams HP Jr. Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol. 2003 Jan. 60(1):21-5. [View Abstract]
  29. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med. 1993 Sep. 22(9):1413-8. [View Abstract]
  30. Borron SW, Baud FJ, Mégarbane B, Bismuth C. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med. 2007 Jun. 25(5):551-8. [View Abstract]
  31. Borron SW, Baud FJ, Barriot P, Imbert M, Bismuth C. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. Ann Emerg Med. 2007 Jun. 49(6):794-801, 801.e1-2. [View Abstract]
  32. DesLauriers CA, Burda AM, Wahl M. Hydroxocobalamin as a cyanide antidote. Am J Ther. 2006 Mar-Apr. 13(2):161-5. [View Abstract]
  33. Hall AH, Saiers J, Baud F. Which cyanide antidote?. Crit Rev Toxicol. 2009. 39(7):541-52. [View Abstract]
  34. Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med. 1994 Jul. 24(1):65-7. [View Abstract]
  35. Sutter M, Tereshchenko N, Rafii R, Daubert GP. Hemodialysis Complications of Hydroxocobalamin: A Case Report. J Med Toxicol. 2010 Mar 30. [View Abstract]
  36. Shepherd G, Velez LI. Role of hydroxocobalamin in acute cyanide poisoning. Ann Pharmacother. 2008 May. 42(5):661-9. [View Abstract]